Urapidil: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
No edit summary |
||
Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
| IUPAC_name | | IUPAC_name = 6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethylpyrimidine-2,4(1''H'',3''H'')-dione | ||
| image = Urapidil.png | |||
| | |||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|international|urapidil}} | |||
| pregnancy_category = | |||
| legal_status = Rx-only | |||
| routes_of_administration = Oral | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = | |||
| metabolism = | |||
| elimination_half-life = | |||
| excretion = | |||
<!--Identifiers--> | |||
| CAS_number = 34661-75-1 | |||
| CAS_supplemental = <br />64887-14-5 ([[Hydrochloride|HCl]]) | |||
| ATC_prefix = C02 | |||
| ATC_suffix = CA06 | |||
| PubChem = 5639 | |||
| ChemSpiderID = 5437 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = A78GF17HJS | |||
| ChEMBL = 279229 | |||
<!--Chemical data--> | |||
| C=20 | H=29 | N=5 | O=3 | |||
| molecular_weight = 387.48 g/mol | |||
| smiles = O=C1\C=C(/N(C(=O)N1C)C)NCCCN3CCN(c2ccccc2OC)CC3 | |||
}} | |||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
{{ | ==Overview== | ||
'''Urapidil''' is a [[sympatholytic]] [[antihypertensive]] [[drug]]. It acts as an [[alpha-1 adrenoceptor|α<sub>1</sub>-adrenoceptor]] [[receptor antagonist|antagonist]] and as an [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[agonist]]<ref name="pmid1855130">{{cite journal |author=Ramage AG |title=The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors |journal=Br. J. Pharmacol. |volume=102 |issue=4 |pages=998–1002 |date=April 1991 |pmid=1855130 |pmc=1917978 |doi= |url=}}</ref> Although an initial report suggested that urapidil was also an [[alpha-2 adrenoceptor|α<sub>2</sub>-adrenoceptor]] [[agonist]],<ref name="pmid228944">{{cite journal|author=Eltze M |title=Investigations on the mode of action of a new antihypertensive drug, urapidil, in the isolated vas deferens |journal=Eur. J. Pharmacol. |volume=59 |pages=1–9 |year=1979 |doi= 10.1016/0014-2999(79)90018-9|url=|pmid=228944|issue=1–2}}</ref> this was not substantiated in later studies that demonstrated it was devoid of agonist actions in the dog saphenous vein and the guinea-pig ileum.<ref name="pmid6097380">{{cite journal |author=Verberne AJM, Rand MJ |title=Pharmacological activities of the antihypertensive drug urapidil in the rat |journal=Clin. Exp. Pharmacol. Physiol. |volume=11 |pages=407–412 |year=1984 |doi= 10.1111/j.1440-1681.1984.tb00289.x|url= |pmid=6097380 |issue=4}}</ref> Unlike some other [[alpha-1 adrenoceptor|α<sub>1</sub>-adrenoceptor]] [[receptor antagonist|antagonists]], urapidil does not elicit reflex tachycardia, and this may be related to its weak [[beta-1 adrenoceptor|β<sub>1</sub>-adrenoceptor]] [[receptor antagonist|antagonist]] activity,<ref name="">{{cite book |author=Schoetensack W, Bruckschen EG, Zech K |title=Urapidil |pages=19 |year=1983 |doi= |url= |work=New Drugs Annual: Cardiovascular Drugs}}</ref><ref name="pmid2984023">{{cite journal |author=Verberne AJM, Rand MJ |title=Effect of urapidil on β-adrenoceptors of rat atria |journal=Eur. J. Pharmacol. |volume=108 |pages=193–196 |year=1985 |doi= 10.1016/0014-2999(85)90725-3|url= |pmid=2984023 |issue=2}}</ref> as well as its effect on cardiac vagal drive.<ref name="pmid1702490">{{cite journal |author=Ramage AG |title=Influence of 5-HT1A receptor agonists on sympathetic and parasympathetic nerve activity |journal=J. Cardiovasc. Pharmacol. |volume=15 |pages=S75–S85 |year=1990 |doi= |url= |pmid=1702490}}</ref> Urapidil is currently not approved by the [[Food and Drug Administration|U.S. Food and Drug Administration]], but it is available in [[Europe]]. | |||
== See Also == | |||
[[ | * [[Naftopidil]] | ||
== References == | |||
{{Reflist|2}} | |||
{{Antihypertensives}} | |||
{{Adrenergics}} | |||
{{Serotonergics}} | |||
{{Piperazines}} | |||
[[Category:Alpha blockers]] | |||
[[Category:Antihypertensive agents]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] |
Revision as of 23:25, 24 July 2014
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C20H29N5O3 |
Molar mass | 387.48 g/mol |
3D model (JSmol) | |
|
WikiDoc Resources for Urapidil |
Articles |
---|
Most recent articles on Urapidil |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Urapidil at Clinical Trials.gov Clinical Trials on Urapidil at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Urapidil
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating Urapidil Risk calculators and risk factors for Urapidil
|
Healthcare Provider Resources |
Causes & Risk Factors for Urapidil |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Urapidil is a sympatholytic antihypertensive drug. It acts as an α1-adrenoceptor antagonist and as an 5-HT1A receptor agonist[1] Although an initial report suggested that urapidil was also an α2-adrenoceptor agonist,[2] this was not substantiated in later studies that demonstrated it was devoid of agonist actions in the dog saphenous vein and the guinea-pig ileum.[3] Unlike some other α1-adrenoceptor antagonists, urapidil does not elicit reflex tachycardia, and this may be related to its weak β1-adrenoceptor antagonist activity,[4][5] as well as its effect on cardiac vagal drive.[6] Urapidil is currently not approved by the U.S. Food and Drug Administration, but it is available in Europe.
See Also
References
- ↑ Ramage AG (April 1991). "The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors". Br. J. Pharmacol. 102 (4): 998–1002. PMC 1917978. PMID 1855130.
- ↑ Eltze M (1979). "Investigations on the mode of action of a new antihypertensive drug, urapidil, in the isolated vas deferens". Eur. J. Pharmacol. 59 (1–2): 1–9. doi:10.1016/0014-2999(79)90018-9. PMID 228944.
- ↑ Verberne AJM, Rand MJ (1984). "Pharmacological activities of the antihypertensive drug urapidil in the rat". Clin. Exp. Pharmacol. Physiol. 11 (4): 407–412. doi:10.1111/j.1440-1681.1984.tb00289.x. PMID 6097380.
- ↑ Schoetensack W, Bruckschen EG, Zech K (1983). Urapidil. New Drugs Annual: Cardiovascular Drugs. p. 19.
- ↑ Verberne AJM, Rand MJ (1985). "Effect of urapidil on β-adrenoceptors of rat atria". Eur. J. Pharmacol. 108 (2): 193–196. doi:10.1016/0014-2999(85)90725-3. PMID 2984023.
- ↑ Ramage AG (1990). "Influence of 5-HT1A receptor agonists on sympathetic and parasympathetic nerve activity". J. Cardiovasc. Pharmacol. 15: S75–S85. PMID 1702490.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles containing unverified chemical infoboxes
- Alpha blockers
- Antihypertensive agents
- Cardiovascular Drugs
- Drug